{
    "clinical_study": {
        "@rank": "97578", 
        "acronym": "LYDIA", 
        "arm_group": {
            "arm_group_label": "Activated natural killer cells", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To determine safety profile of immunotherapy with natural killer cells and activated\n      expanded (NKAEs) after salvage chemotherapy in children, adolescents and young adults with\n      relapsed or refractary acute leukemia"
        }, 
        "brief_title": "\"LANK-2\": Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute Leukemia", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Relapsed/Refractory Paediatric Acute Leukaemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Acute Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients between 0 and 23 years of age with diagnosis of acute lymphoblastic\n             leukemia, in second relapse situation, posttransplant relapse or refractary, or\n\n          2. Patients between 0 and 23 years of age with diagnosis of acute myeloblastic leukemia,\n             relapsed or refractary. (Patient must meet inclusion criteria 1 or 2)\n\n          3. Lansky index > 60%\n\n          4. Mild (<2) functional organs alteration (hepatic, renal, respiratory) according to\n             National Cancer Institute criteria (NCI CTCAE v4).\n\n          5. Left ventricular ejection fraction > 39%\n\n          6. To grant informed consent in accordance with the current legal regulations.\n\n          7. Presence of a compatible haploidentical donor (father or mother or brother).\n\n        Exclusion Criteria:\n\n          1. Patients with history of bad therapeutical compliance\n\n          2. Patients not valid after psycho-social evaluation\n\n          3. Positive HIV serology"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "23 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02074657", 
            "org_study_id": "2012-005146-38"
        }, 
        "intervention": {
            "arm_group_label": "Activated natural killer cells", 
            "description": "Activated and expanded natural killer cells (NKAEs) from haploidentical donor", 
            "intervention_name": "Activated and expanded natural killer cells (NKAEs)", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Immunotherapy", 
            "NKAEs", 
            "Expanded haploidentical natural killer cells", 
            "Activated natural killer cells"
        ], 
        "lastchanged_date": "April 25, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28046"
                    }, 
                    "name": "Hospital Infantil Universitario La Paz"
                }, 
                "investigator": {
                    "last_name": "Antonio P\u00e9rez Mart\u00ednez, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jmartinezlo@hematologia12octubre.com", 
                    "last_name": "Joaqu\u00edn Mart\u00ednez-L\u00f3pez, MD", 
                    "phone": "+34917792787"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }, 
                    "name": "Hospital 12 de Octubre"
                }, 
                "investigator": {
                    "last_name": "Joaqu\u00edn Mart\u00ednez-L\u00f3pez, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "official_title": "\"LANK-2\": Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute Leukemia", 
        "overall_contact": {
            "email": "aperezmartinez@salud.madrid.org", 
            "last_name": "Antonio P\u00e9rez-Mart\u00ednez, MD, PhD", 
            "phone": "+34917277223"
        }, 
        "overall_official": {
            "affiliation": "Hospital Infantil Universitario La Paz", 
            "last_name": "Antonio P\u00e9rez-Mart\u00ednez, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of patients with adverse events according to NCI-CTCAE v4.0 CRITERIA as a measure of safety and tolerability", 
            "measure": "To assess the safety of activated and expanded NK cell (NKAE) immunotherapy after salvage chemotherapy in patients with relapsed or refractary acute leukemia", 
            "safety_issue": "Yes", 
            "time_frame": "2 months after infusion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02074657"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hospital Universitario La Paz", 
            "investigator_full_name": "Antonio P\u00e9rez Mart\u00ednez", 
            "investigator_title": "MD, Servicio de Hemato-Oncolog\u00eda Pedi\u00e1trica", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of episodes of febrile neutropenia, bacteriemia or viral or fungal infections", 
                "safety_issue": "Yes", 
                "time_frame": "End of infusion and follow-up (2 months and 1 year)"
            }, 
            {
                "measure": "Days of hematological recovery (neutrophils >500/microL, lymphocytes >250/microL and platelets >50.000/microL), days of hospitalization, in each cycle Immune", 
                "safety_issue": "No", 
                "time_frame": "End of infusion and follow-up (2 months and 1 year)"
            }, 
            {
                "measure": "Objective response rate according to cytomorphic and by \"minimal residual disease\" criteria (cytometry and/or real time PCR) at the end of the treatment", 
                "safety_issue": "No", 
                "time_frame": "End of infusion and follow-up (2 months and 1 year)"
            }, 
            {
                "measure": "Immune reconstitution: Median of T-cell , B, NK, Natural Killer T cell (NKT) and dendritic cells count and subpopulations of T and NK lymphocytes (cel/microL) during posttreatment follow-up period.", 
                "safety_issue": "No", 
                "time_frame": "End of infusion and follow-up (2 months and 1 year)"
            }
        ], 
        "source": "Hospital Universitario La Paz", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hospital Universitario La Paz", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}